Thank you for the opportunity to review the manuscript titled "Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with obesity: protocol for a systematic review and meta-analysis." This manuscript describes the planned protocol and methodology for a meta-analysis of randomized, controlled trial with lorcaserin on specific endpoints related to weight loss and glycemic control. However, the concern with this manuscript and research project is the low number of randomized, controlled trials involving lorcaserin. There are a handful of studies, which would be included, which may make it difficult to thorough analyze results and provide discussion for clinical
GENERAL COMMENTS
Many thanks for the opportunity to review this interesting systematic review and meta-analysis protocol for lorcaserin for prevention of T2DM
I note from the PROSPERO protocol registration page that this review was scheduled for completion on 13 February 2019. Has this review, in fact, already been completed before the submission of this protocol to BMJ Open? You report that the review was to December 2018, which is prior to the date of my reading of this manuscript.
You plan to compare locaserin to no intervention. By this do you mean treatment as usual? You later state that only RCTs will be included.
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GENERAL COMMENTS
Thank you for the opportunity to review the manuscript titled "Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with obesity: protocol for a systematic review and meta-analysis." This manuscript describes the planned protocol and methodology for a meta-analysis of randomized, controlled trial with lorcaserin on specific endpoints related to weight loss and glycemic control. However, the concern with this manuscript and research project is the low number of randomized, controlled trials involving lorcaserin. There are a handful of studies, which would be included, which may make it difficult to thorough analyze results and provide discussion for clinical application. The authors may need to concern a different approach after reviewing interventions and types of studies.
VERSION 1 -AUTHOR RESPONSE
Reviewer ( Many thanks for the opportunity to review this interesting systematic review and meta-analysis protocol for lorcaserin for prevention of T2DM.
Reviewer comment
Author's reply:
Dear reviewer, thanks a lot for your comments. We initially anticipated to start the review on 1st January 2019. However, the anticipated start date of this study was delayed for several reasons, and it requires a large amount of time to complete this work. Thus, we have updated the start and completion date for our study in the PROSPERO entry. We anticipate to complete the main body of this review in June 2019, meanwhile, the dates of the systematic literature searches will be up to date as of June 2019. The current status of this review is ongoing.
You plan to compare lorcaserin to no intervention. By this do you mean treatment as usual? You later state that only RCTs will be included.
For the following sentence in the methods section, "we plan to investigate the comparisons of lorcaserin versus placebo or no intervention". Actually, we are going to investigate the comparisons of lorcaserin versus placebo, thus, "no intervention" is redundant. We have corrected this sentence and deleted "no intervention".
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Thank you for the opportunity to review the manuscript titled "Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with obesity: protocol for a systematic review and meta-analysis." This manuscript describes the planned protocol and methodology for a meta-analysis of randomized, controlled trial with lorcaserin on specific endpoints related to weight loss and glycemic control.
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However, the concern with this manuscript and research project is the low number of randomized, controlled trials involving lorcaserin. There are a handful of studies, which would be included, which may make it difficult to thorough analyze results and provide discussion for clinical application. The authors may need to concern a different approach after reviewing interventions and types of studies.
Dear reviewer, we sincerely appreciate for your suggestions. In preliminary literature searches, several well-designed large-scale randomized, double-blind, placebo-controlled trials were identified, including BLOOM, BLOSSOM, BLOOM-DM, and CAMELLIA-TIMI 61 trial and involving more than 13600 patients. To include more relevant studies and provide more reliable evidence, we will continuously update comprehensive systematic search of various databases (including PubMed, Embase, Web of Science, the Cochrane library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform) in following study process. However, common to any meta-analysis, the interpretation of our findings may be influenced by the quantity of included studies.
In the case of limited number of available trials, we will consider it as a limitation of this study. We will also present a narrative review simultaneously and interpret the findings of our study cautiously. The conclusions of this study will provide valuable implications for patients with coexisting prediabetes or T2DM and obesity, guideline developers, and clinicians. GENERAL COMMENTS all comments have been addressed
